Paul Blanchfield
President bei LANTHEUS HOLDINGS, INC.
Vermögen: 6 Mio $ am 31.03.2024
Profil
Paul Blanchfield is currently the President at Lantheus Holdings, Inc. He previously worked as the General Manager-Nordic Baltics at Shire Plc and as the Head-US Immunology Business Unit at Takeda Pharmaceutical Co., Ltd.
Mr. Blanchfield completed his undergraduate degree at Duke University and holds graduate degrees, including an MBA, from Stanford University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
LANTHEUS HOLDINGS INC
0,15% | 17.04.2024 | 102 677 ( 0,15% ) | 6 Mio $ | 31.03.2024 |
Aktive Positionen von Paul Blanchfield
| Unternehmen | Position | Beginn |
|---|---|---|
| LANTHEUS HOLDINGS, INC. | President | 20.03.2023 |
Ehemalige bekannte Positionen von Paul Blanchfield
| Unternehmen | Position | Ende |
|---|---|---|
Shire Plc /Old/
 Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Corporate Officer/Principal | - |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Corporate Officer/Principal | - |
Ausbildung von Paul Blanchfield
| Duke University | Undergraduate Degree |
| Stanford University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
| LANTHEUS HOLDINGS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Commercial Services |
